FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 16 (6) , 844-847
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Speed, Safety, and Industry Funding — From PDUFA I to PDUFA VINew England Journal of Medicine, 2017
- The Fate of FDA Postapproval StudiesNew England Journal of Medicine, 2017
- FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review OutcomesClinical Pharmacology & Therapeutics, 2014
- The Food and Drug Administration Amendments Act and Postmarketing CommitmentsJAMA, 2013
- Drug-Review Deadlines and Safety ProblemsNew England Journal of Medicine, 2008